Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients

Table 5 Multivariate logistic regression analysis of independent relations with loss of CDX2 expression in colorectal cancers

Variables	OR (95%CI)	P value
Differentiation (differentiated/ undifferentiated)	4.98 (1.42-17.49)	0.012
CK7 expression (expression/ no-expression)	11.21 (4.64-27.11)	< 0.001
CK20 expression (loss/retained)	2.90 (1.08-7.77)	0.034
CIMP (CIMP-high/CIMP-0, low)	7.78 (2.85-21.23)	< 0.001
Tumor location (proximal/distal, rectum)	1.83 (0.79-4.26)	0.162
Gross type (infiltrative/fungating)	1.67 (0.74-3.81)	0.220
T category (T1, 2/T3, 4)	3.66 (0.44-30.17)	0.229
N category (N0/N1, 2)	1.77 (0.69-4.53)	0.233
M category (M0/M1)	1.69 (0.62-4.62)	0.310
MSI (MSI-high/MSS, MSI-low)	1.55 (0.51-4.75)	0.441
BRAF mutation (Mt/Wt)	3.13 (0.95-10.37)	0.062

CIMP: CpG island methylator phenotype; MSI: Microsatellite instability; MSS: Microsatellite stable; Mt: Mutant type; Wt: Wild type; CK: Cytokeratin.